Related references
Note: Only part of the references are listed.Treatable Traits in Airway Disease: From Theory to Practice
Alvar Agusti et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update
Mark L. Levy et al.
NPJ PRIMARY CARE RESPIRATORY MEDICINE (2023)
IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline
George Scott et al.
CYTOKINE (2023)
Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease
Archana Shankar et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
What has been learned by cytokine targeting of asthma?
William W. Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)
Stanley J. Szefler et al.
CLINICAL AND TRANSLATIONAL ALLERGY (2022)
High throughput virtual screening strategy to develop a potential treatment for bronchial asthma by targeting interleukin 13 cytokine signaling
Qin Ma et al.
ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2022)
Virus-like particle vaccinology, from bench to bedside
Mona O. Mohsen et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2022)
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis
Evan S. Dellon et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Regulation of the humoral type 2 immune response against allergens and helminths
Paul Haase et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
JAK inhibitors for asthma
Steve N. Georas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial
Irene E. Braithwaite et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice
Eva Conde et al.
NATURE COMMUNICATIONS (2021)
Tezepelumab normalizes serum interleukin-5 and-13 levels in patients with severe, uncontrolled asthma
Tuyet-Hang Pham et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Tralokinumab: First Approval
Sean Duggan
DRUGS (2021)
Upadacitinib-induced remission of allergic asthma: A case report
Diana Betancor et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
The Role of Dupilumab in Severe Asthma
Fabio Luigi Massimo Ricciardolo et al.
BIOMEDICINES (2021)
Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, antiinterleukin-5 or anti-immunoglobulin-E agents, for people with asthma
Andrew Gallagher et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)
Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis
Thomas Bieber
ALLERGY (2020)
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc'h et al.
ALLERGY (2020)
TSLP Inhibitors for Asthma: Current Status and Future Prospects
Maria Gabriella Matera et al.
DRUGS (2020)
Transcriptional regulation of the IL-13Rα2 gene in human lung fibroblasts
Loka R. Penke et al.
SCIENTIFIC REPORTS (2020)
Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma
Gail M. Gauvreau et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
Cary D. Austin et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
The interleukin-13 paradox in asthma: effective biology, ineffective biologicals
Parameswaran Nair et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats
Marta Calbet et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Periostin is induced by IL-4/IL-13 in dermal fibroblasts and promotes RhoA/ROCK pathway-mediated TGF-β1 secretion in abnormal scar formation
Daisuke Maeda et al.
JOURNAL OF PLASTIC SURGERY AND HAND SURGERY (2019)
The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis
Yan Zhang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling
Mark Zak et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
William W. Busse et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers
Tracy L. Staton et al.
BMC PULMONARY MEDICINE (2019)
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
Giancarlo Marone et al.
FRONTIERS IN PHARMACOLOGY (2019)
Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine
John Foerster et al.
VACCINES (2019)
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction
Eleanor M. Dunican et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Richard J. Russell et al.
LANCET RESPIRATORY MEDICINE (2018)
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A. Panettieri et al.
LANCET RESPIRATORY MEDICINE (2018)
Tuning the Cytokine Responses: An Update on interleukin (IL)-4 and IL-13 Receptor Complexes
Ilkka S. Junttila
FRONTIERS IN IMMUNOLOGY (2018)
IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View
Achsah D. Keegan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies
Sathyadevi Venkataramani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Modulating Interleukins and their Receptors Interactions with Small Chemicals Using In Silico Approach for Asthma
Sreyashi Majumdar et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Periostin and Dipeptidyl Peptidase-4 Potential Biomarkers of Interleukin 13 Pathway Activation in Asthma and Allergy
Claire Emson et al.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2018)
Bronchial Allergen Challenge of Patients with Atopic Asthma Triggers an Alarmin (IL-33, TSLP, and IL-25) Response in the Airways Epithelium and Submucosa
Wei Wang et al.
JOURNAL OF IMMUNOLOGY (2018)
Anti-interleukin 13 for asthma: stick or twist?
Brian Lipworth et al.
LANCET RESPIRATORY MEDICINE (2018)
Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942
Gary Burgess et al.
EBIOMEDICINE (2018)
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Marina Amaral de Avila Machado et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2
B. Popovic et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Interleukin-13 peptide vaccine induces protective humoral immunity in murine asthma models
Fengbo Wu et al.
Oncotarget (2017)
The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA
Robert Y. Suruki et al.
BMC PULMONARY MEDICINE (2017)
RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study
Catherine S. Tripp et al.
ADVANCES IN THERAPY (2017)
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma
Luke R. Bonser et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Bioanalytical challenges and improved detection of circulating levels of IL-13
Fang Cai et al.
BIOANALYSIS (2016)
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania et al.
LANCET RESPIRATORY MEDICINE (2016)
Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease
Peter J. Barnes
PHARMACOLOGICAL REVIEWS (2016)
The differential expression of IL-4 and IL-13 and its impact on type-2 immunity
Katherine Bao et al.
CYTOKINE (2015)
Strategies targeting the IL-4/IL-13 axes in disease
Richard D. May et al.
CYTOKINE (2015)
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
Nicola A. Hanania et al.
THORAX (2015)
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
Christopher E. Brightling et al.
LANCET RESPIRATORY MEDICINE (2015)
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
H. Scheerens et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2014)
Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma
Swati Agrawal et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial
Erika H. De Boever et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses
Shigeru Ashino et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics
Peter Hodsman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study
Bart van Hartingsveldt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Role of Interleukin-13 in Asthma
Jonathan Corren
CURRENT ALLERGY AND ASTHMA REPORTS (2013)
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Edward Piper et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
IL-13 receptor α2 contributes to development of experimental allergic asthma
Weiguo Chen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab
Mark Ultsch et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma
R. D. May et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients
Guiquan Jia et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma
Gail M. Gauvreau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Transcriptional regulation by STAT6
Shreevrat Goenka et al.
IMMUNOLOGIC RESEARCH (2011)
IL-13 Antibodies Influence IL-13 Clearance in Humans by Modulating Scavenger Activity of IL-13Rα2
Marion T. Kasaian et al.
JOURNAL OF IMMUNOLOGY (2011)
Lebrikizumab Treatment in Adults with Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma
C. K. Oh et al.
EUROPEAN RESPIRATORY REVIEW (2010)
Interleukin-13 Augments Bronchial Smooth Muscle Contractility with an Up-Regulation of RhoA Protein
Yoshihiko Chiba et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2009)
Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system
Sherry L. LaPorte et al.
CELL (2008)
IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells
K. Chibana et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2008)
Increased sputum and bronchial biopsy IL-13 expression in severe asthma
Shironjit K. Saha et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys
Marion T. Kasaian et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
IL-13Rα2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice
Mark S. Wilson et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
IL-13 receptor isoforms: Breaking through the complexity
Yasuhiro Tabata et al.
CURRENT ALLERGY AND ASTHMA REPORTS (2007)
Eotaxin-3/CCL26 gene expression in intestinal epithelial cells is up-regulated by interleukin-4 and interleukin-13 via the signal transducer and activator of transcription 6
C Blanchard et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Anti-interleukin-4 therapy
JW Steinke
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2004)
The negative-feedback regulation of the IL-13 signal by the IL-13 receptor α2 chain in bronchial epithelial cells
S Yasunaga et al.
CYTOKINE (2003)
Kinetic analysis of the interleukin-13 receptor complex
AL Andrews et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma
DA Kuperman et al.
NATURE MEDICINE (2002)
IL-13 induces eosinophil recruitment into the lung by an IL-5-and eotaxin-dependent mechanism
SM Pope et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Share Paper
